(Q35640651)

9 August 2017

1 reference

title

The patient with hormone-refractory prostate cancer: determining who, when, and how to treat (English)

1 reference

9 August 2017

1 reference

Elizabeth C Kent

1

1 reference

9 August 2017

Maha H A Hussain

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

62 Suppl 1

1 reference

9 August 2017

page(s)

134-140

1 reference

9 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Flow microfluorometry and transrectal fine-needle biopsy in the classification of human prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

DNA pattern and cytological findings in fine‐needle aspirates of untreated prostatic tumors. A flow‐cytofluorometric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Expression of basal cell keratins in human prostate cancer metastases and cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Treatment options in hormone resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

The androgen receptor gene and its influence on the development and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Activation of the human androgen receptor through a protein kinase A signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Role of stroma in carcinogenesis of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

The role of diethylstilbestrol in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

Importance of continued testicular suppression in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.005

10.1016/J.UROLOGY.2003.09.005

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference